Scribd Logo
Upload

Welcome to Scribd!

  • 82 views

    Treatment of Depersonalization Disorder With Clomipramine

    Uploaded by

    Amy Powers
    This study evaluated the effectiveness of clomipramine, a potent serotonin reuptake inhibitor, in treating depersonalization disorder. Eight subjects with depersonalization disorder participated in a double-blind crossover trial with 8 weeks of clomipramine and 8 weeks of desipramine. Two subjects showed significant improvement in symptoms with clomipramine, while one showed improvement with desipramine. One clomipramine responder maintained remission for 4 years with continued clomipramine treatment. The study concludes that clomipramine may be a promising treatment for depersonalization disorder, warranting further research.

    Copyright:

    © All Rights Reserved
    Download as DOCX, PDF, TXT or read online from Scribd

    Treatment of Depersonalization Disorder With Clomipramine

    Uploaded by

    Amy Powers
    82 views1 page
    This study evaluated the effectiveness of clomipramine, a potent serotonin reuptake inhibitor, in treating depersonalization disorder. Eight subjects with depersonalization disorder participated in a double-blind crossover trial with 8 weeks of clomipramine and 8 weeks of desipramine. Two subjects showed significant improvement in symptoms with clomipramine, while one showed improvement with desipramine. One clomipramine responder maintained remission for 4 years with continued clomipramine treatment. The study concludes that clomipramine may be a promising treatment for depersonalization disorder, warranting further research.

    Original Description:

    dbt

    Original Title

    Dpd Abstracts

    Copyright

    © © All Rights Reserved

    Available Formats

    DOCX, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    This study evaluated the effectiveness of clomipramine, a potent serotonin reuptake inhibitor, in treating depersonalization disorder. Eight subjects with depersonalization disorder participated in a double-blind crossover trial with 8 weeks of clomipramine and 8 weeks of desipramine. Two subjects showed significant improvement in symptoms with clomipramine, while one showed improvement with desipramine. One clomipramine responder maintained remission for 4 years with continued clomipramine treatment. The study concludes that clomipramine may be a promising treatment for depersonalization disorder, warranting further research.

    Copyright:

    © All Rights Reserved
    Download as DOCX, PDF, TXT or read online from Scribd
    Download as docx, pdf, or txt
    82 views1 page

    Treatment of Depersonalization Disorder With Clomipramine

    Uploaded by

    Amy Powers
    This study evaluated the effectiveness of clomipramine, a potent serotonin reuptake inhibitor, in treating depersonalization disorder. Eight subjects with depersonalization disorder participated in a double-blind crossover trial with 8 weeks of clomipramine and 8 weeks of desipramine. Two subjects showed significant improvement in symptoms with clomipramine, while one showed improvement with desipramine. One clomipramine responder maintained remission for 4 years with continued clomipramine treatment. The study concludes that clomipramine may be a promising treatment for depersonalization disorder, warranting further research.

    Copyright:

    © All Rights Reserved
    Download as DOCX, PDF, TXT or read online from Scribd
    Download as docx, pdf, or txt
    of 1

    Treatment of depersonalization disorder with clomipramine (Citations: 15)

    Daphne Simeon, Dan J. Stein, Eric Hollander


    Background: Although there is a dire paucity of data on the pharmacologic treatment of depersonalization
    disorder, there have been a few reports in the literature suggesting that selective serotonin reuptake
    inhibitors may be of therapeutic benefit. In this study, we undertook to evaluate the efficacy of the potent
    serotonin reuptake inhibitor clomipramine in treating depersonalization.Methods: Eight subjects with
    DSM-III-R depersonalization disorder were entered into a double-blind crossover trial consisting of 8
    weeks desipramine and 8 weeks clomipramine. Due to the very small size of the trial findings are
    presented descriptively.Results: Of 7 subjects who entered the clomipramine trial, two showed significant
    improvement in depersonalization. Three subjects dropped out early, unable to tolerate adverse effects.
    Of 6 subjects who entered the desipramine trial, 1 showed significant improvement in depersonalization.
    One clomipramine responder was subsequently followed in open maintenance treatment with
    clomipramine for 4 years, and her depersonalization symptoms remained in almost complete remission,
    with relapses upon each attempt to taper off or switch medication.Conclusions: Clomipramine may be a
    promising pharmacologic treatment for primary depersonalization disorder and warrants further
    investigation.
    Journal: Biological Psychiatry - BIOL PSYCHIAT , vol. 44, no. 4, pp. 302-303, 1998
    DOI: 10.1016/S0006-3223(98)00023-7

    Effect of naloxone therapy on depersonalization: a pilot study (Citations:


    9)

    Yuri L. Nuller, Marina G. Morozova, Olga N. Kushnir, Nikita Hamper


    To test the hypothesis of the role for the opioid system in the pathogenesis of depersonalization, the
    effect of naloxone (an opioid receptor blocker) on the symptoms and corticosteroids secretion was
    studied in patients with depersonalization syndrome. Fourteen depersonalization patients were treated
    with naloxone: 11 patients received single doses (1.6 or 4 mg i.v.) and three others received multiple
    infusions, with the maximal dosage being 10 mg, and the effect of naloxone on symptom severity was
    determined. In eight patients, the cortisol, cortisone and corticosterone content in the blood plasma was
    determined prior to and after the 4 mg naloxone infusion. A reversed-phase microcolumn high-
    performance liquid chromatography with ultraviolet detection was applied for assessment of
    glucocorticoids. In three of 14 patients, depersonalization symptoms disappeared entirely and seven
    patients showed a marked improvement. The therapeutic effect of naloxone provides evidence for the
    role of the endogenous opioid system in the pathogenesis of depersonalization.
    Journal: Journal of Psychopharmacology - J PSYCHOPHARMACOL , vol. 15, no. 2, pp.
    93-95, 2001
    DOI: 10.1177/026988110101500205

    You might also like

    pFad - Phonifier reborn

    Pfad - The Proxy pFad of © 2024 Garber Painting. All rights reserved.

    Note: This service is not intended for secure transactions such as banking, social media, email, or purchasing. Use at your own risk. We assume no liability whatsoever for broken pages.


    Alternative Proxies:

    Alternative Proxy

    pFad Proxy

    pFad v3 Proxy

    pFad v4 Proxy